

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/2445296/publications.pdf>

Version: 2024-02-01

53
papers

3,684
citations

201658
27
h-index

189881
50
g-index

55
all docs

55
docs citations

55
times ranked

4449
citing authors

#	ARTICLE	IF	CITATIONS
1	The proton-activated ovarian cancer G α protein-coupled receptor 1 (OGR1) is responsible for renal calcium loss during acidosis. <i>Kidney International</i> , 2020, 97, 920-933.	5.2	22
2	Bone Measurements by Peripheral Quantitative Computed Tomography in Rodents. <i>Methods in Molecular Biology</i> , 2019, 1914, 533-558.	0.9	2
3	Bone Physiology and Biology. <i>Molecular and Integrative Toxicology</i> , 2017, , 27-94.	0.5	13
4	Therapy for musculoskeletal disorders. <i>Journal of Orthopaedic Translation</i> , 2016, 4, 71-74.	3.9	2
5	Protein Malnutrition Attenuates Bone Anabolic Response to PTH in Female Rats. <i>Endocrinology</i> , 2015, 156, 419-428.	2.8	8
6	Effect of chronic metabolic acidosis on bone density and bone architecture in vivo in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, F517-F524.	2.7	29
7	Effects of 3 \hat{A} years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients. <i>Osteoporosis International</i> , 2013, 24, 339-347.	3.1	41
8	Coronal Vertebral Clefts: A Radiological Indicator for Chromosomal Aberrations. <i>Pediatric and Developmental Pathology</i> , 2013, 16, 1-6.	1.0	10
9	Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 442-448.	2.8	26
10	Bone Measurements by Peripheral Quantitative Computed Tomography in Rodents. <i>Methods in Molecular Biology</i> , 2012, 816, 477-498.	0.9	10
11	Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 12-18.	2.8	82
12	Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1 \hat{A} €“34)] in postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 503-511.	2.8	291
13	Circulating fibronectin affects bone matrix, whereas osteoblast fibronectin modulates osteoblast function. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 706-715.	2.8	79
14	Interleukin-1 is essential for systemic inflammatory bone loss. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 284-290.	0.9	118
15	PTH effects on bone are attenuated in protein malnourished rats. <i>Bone</i> , 2010, 47, S170.	2.9	0
16	TGF \times ² and loading increases osteocyte survival in human cancellous bone cultured \times ex vivo. <i>Cell Biochemistry and Function</i> , 2009, 27, 23-29.	2.9	18
17	Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 6-16.	2.8	189
18	Long-Term Protective Effects of Zoledronic Acid on Cancellous and Cortical Bone in the Ovariectomized Rat. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 544-551.	2.8	90

#	ARTICLE	IF	CITATIONS
19	Bone Degeneration and Recovery after Early and Late Bisphosphonate Treatment of Ovariectomized Wistar Rats Assessed by InÃVivo Micro-Computed Tomography. Calcified Tissue International, 2008, 82, 202-211.	3.1	76
20	Models of tibial fracture healing in normal and Nf1Ãdeficient mice. Journal of Orthopaedic Research, 2008, 26, 1053-1060.	2.3	56
21	European Society of Biomechanics S.M. Perren Award 2008: Using temporal trends of 3D bone micro-architecture to predict bone quality. Journal of Biomechanics, 2008, 41, 2946-2953.	2.1	11
22	Spatial and temporal patterns of bone formation in ectopically preÃfabricated, autologous cellÃbased engineered bone flaps in rabbits. Journal of Cellular and Molecular Medicine, 2008, 12, 1238-1249.	3.6	28
23	A Cathepsin K Inhibitor Reduces Breast CancerÃInduced Osteolysis and Skeletal Tumor Burden. Cancer Research, 2007, 67, 9894-9902.	0.9	180
24	Dlk1/FA1 Is a Novel Endocrine Regulator of Bone and Fat Mass and Its Serum Level Is Modulated by Growth Hormone. Endocrinology, 2007, 148, 3111-3121.	2.8	65
25	Antitumor Effects of Clinical Dosing Regimens of Bisphosphonates in Experimental Breast Cancer Bone Metastasis. Journal of the National Cancer Institute, 2007, 99, 322-330.	6.3	213
26	TNF-induced structural joint damage is mediated by IL-1. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11742-11747.	7.1	273
27	Conditional transgene expression mediated by the mouse Î²Ãactin locus. Genesis, 2007, 45, 659-666.	1.6	21
28	Continuous or repeated intermittent low-dose therapy with zoledronic acid induces a sustained inhibition of tumor cell trafficking to bone in vivo. Bone, 2006, 38, 44-45.	2.9	1
29	Inhibition of FPP-synthase in osteoblasts may explain the blunting of the bone anabolic response to PTH observed after chronic exposure of rats to bisphosphonates. Bone, 2006, 38, 50-51.	2.9	3
30	A cathepsin k inhibitor (alone or in combination with zoledronic acid) inhibits the progression of breast cancer bone metastases. Bone, 2006, 38, 55-56.	2.9	1
31	Monitoring individual morphological changes over time in ovariectomized rats by in vivo micro-computed tomography. Bone, 2006, 39, 854-862.	2.9	189
32	A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats. Bone, 2006, 39, 787-795.	2.9	24
33	The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them. Current Opinion in Pharmacology, 2006, 6, 313-318.	3.5	10
34	Evaluation of Three-dimensional Image Registration Methodologies for In Vivo Micro-computed Tomography. Annals of Biomedical Engineering, 2006, 34, 1587-1599.	2.5	56
35	The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nature Medicine, 2005, 11, 394-399.	30.7	169
36	Noninvasive monitoring of changes in structural cancellous bone parameters with a novel prototype micro-CT. Journal of Bone and Mineral Metabolism, 2005, 23, 90-96.	2.7	49

#	ARTICLE	IF	CITATIONS
37	Mice Deficient in 11Î²-Hydroxysteroid Dehydrogenase Type 1 Lack Bone Marrow Adipocytes, but Maintain Normal Bone Formation. <i>Endocrinology</i> , 2004, 145, 1916-1925.	2.8	72
38	Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2327-2337.	6.7	105
39	Intravenous administration of zoledronic acid prevents the bone loss and reduction of mechanical properties induced by aromatase inhibition or surgical ovariectomy in rats. <i>Breast</i> , 2003, 12, S42.	2.2	0
40	Skeletal growth and long-term bone turnover after enterocystoplasty in a chronic rat model. <i>BJU International</i> , 2003, 92, 306-313.	2.5	12
41	Proton-sensing G-protein-coupled receptors. <i>Nature</i> , 2003, 425, 93-98.	27.8	616
42	The effect of enterocystoplasty on bone strength assessed at four different skeletal sites in a rat model. <i>Bone</i> , 2003, 33, 549-556.	2.9	10
43	Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). <i>Bone</i> , 2001, 28, 237-250.	2.9	90
44	Influence of a low calcium and phosphorus diet on the anabolic effect of human parathyroid hormone (1-38) in female rats. <i>Bone</i> , 2001, 29, 344-351.	2.9	9
45	Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats. <i>Bone</i> , 1999, 25, 561-569.	2.9	24
46	Perspectives on osteoporosis research: Its focus and some insights from a new paradigm. <i>Calcified Tissue International</i> , 1995, 57, 399-404.	3.1	46
47	Assessing bone quantity by pQCT. <i>Bone</i> , 1995, 17, S145-S154.	2.9	109
48	Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 1726-1734.	2.8	28
49	The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats. <i>Endocrinology</i> , 1994, 134, 2126-2134.	2.8	67
50	Decreased sensitivity to adenosine in platelets from patients with familial hypercholesterolaemia—a change reversed by cholestyramine treatment. <i>European Journal of Clinical Investigation</i> , 1993, 23, 803-811.	3.4	5
51	Altered cellular signalling and decreased platelet sensitivity to adenosine in insulin-dependent diabetic patients with proliferative retinopathy. <i>Cellular Signalling</i> , 1993, 5, 145-153.	3.6	14
52	Comparison of the Effects of Carvedilol, Propranolol, and Verapamil on in vitro Platelet Function in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 1991, 18, S29-S34.	1.9	21
53	Osteoporosis Research with the vivaCT40. , 0, , 451-462.		1